Shandra Eisenga Human Cell and Tissue Product Safety Act

United States118th CongressHR-7188House of Representatives
Updated: Dec 17, 2024

Summary

Shandra Eisenga Human Cell and Tissue Product Safety Act This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards. Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments. The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Bill texts

Available versions
View official text

3 versions available

Timeline

Latest companion bill action

S-3733: Shandra Eisenga Human Cell and Tissue Product Safety Act

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  1. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)

  2. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)

    House of Representatives

  3. Motion to reconsider laid on the table Agreed to without objection.

    House of Representatives

  4. Received in the Senate.

    Senate